Exchange Traded Concepts LLC Buys 16,690 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Exchange Traded Concepts LLC grew its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPXFree Report) by 34.0% in the fourth quarter, Holdings Channel reports. The fund owned 65,819 shares of the company’s stock after acquiring an additional 16,690 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Compass Therapeutics were worth $103,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its holdings in Compass Therapeutics by 577.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 7,855 shares of the company’s stock worth $26,000 after buying an additional 6,695 shares during the period. XTX Topco Ltd bought a new position in Compass Therapeutics in the 2nd quarter worth approximately $35,000. Alliancebernstein L.P. bought a new position in Compass Therapeutics in the 2nd quarter worth approximately $36,000. UBS Group AG boosted its holdings in Compass Therapeutics by 63.5% in the 4th quarter. UBS Group AG now owns 11,819 shares of the company’s stock worth $59,000 after buying an additional 4,591 shares during the period. Finally, ProShare Advisors LLC bought a new position in Compass Therapeutics in the 2nd quarter worth approximately $38,000. 71.01% of the stock is owned by institutional investors.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $2.13 on Friday. Compass Therapeutics, Inc. has a 1 year low of $1.15 and a 1 year high of $3.62. The stock has a market capitalization of $271.55 million, a PE ratio of -6.45 and a beta of 0.76. The company’s 50 day simple moving average is $1.71 and its two-hundred day simple moving average is $1.77.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Thursday.

Read Our Latest Report on Compass Therapeutics

About Compass Therapeutics

(Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Recommended Stories

Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPXFree Report).

Institutional Ownership by Quarter for Compass Therapeutics (NASDAQ:CMPX)

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.